Agmatine Neuroprotection Against TNF-α Induced RGC Apoptosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma and related eye diseases, such as glaucoma, retinopathy, and optic neuropathy, fail to effectively prevent apoptosis in Retinal Ganglion Cells (RGCs), particularly due to mechanisms beyond elevated IntraOcular Pressure and the involvement of TNF-α, which is associated with RGC death and damage.
Innovation Solution
The use of agmatine or its pharmaceutically acceptable salts to protect RGCs from apoptosis by reducing LDH release and cytotoxic effects induced by hypoxia and TNF-α, offering a neuroprotective mechanism that can be administered in various forms, including ophthalmic solutions or injections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments focus on lowering IntraOcular Pressure (IOP), then the progression of glaucoma can be slowed, but RGC apoptosis continues in some patients even after IOP is lowered to appropriate levels
Solution Approach 1:
The patent identifies TNF-α as a harmful factor causing RGC apoptosis through TNF Receptor-1. By using agmatine to block this harmful pathway, the invention converts the understanding of harmful mechanisms into a beneficial treatment approach, preventing RGC death while maintaining the established IOP-lowering strategy
Solution Approach 2:
Agmatine serves as an intermediary substance that blocks the interaction between TNF-α and TNF Receptor-1 on RGCs. This mediator prevents the harmful signaling cascade without interfering with the primary IOP-lowering mechanism, adding a protective layer to conventional treatment
2Reliability
If TNF-α is involved in RGC death through TNF Receptor-1, then neuroprotective effects can be achieved, but current treatments do not effectively prevent this apoptosis
Solution Approach 1:
Agmatine is an endogenous substance naturally present in the body, particularly in the CNS and retina. By utilizing this self-produced compound, the invention leverages the body's own protective mechanisms, enhancing neuroprotection through a substance that requires no external synthesis and integrates naturally with physiological processes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Agmatine effectively prevents hypoxia-induced and TNF-α-induced apoptosis in RGCs, demonstrating significant neuroprotective effects comparable to or exceeding those of Brain-Derived Neurotrophic Factor (BDNF), suggesting its potential as a therapeutic agent for eye diseases like glaucoma, retinopathy, and optic neuropathy.
Implementation Method 1
agmatine or a pharmaceutically allowable salt thereof, and a pharmaceutical composition comprising the same. The method and pharmaceutical composition of the present invention can prevent apoptosis in a Retinal Ganglion Cell (RGC), particularly apoptosis induced by hypoxia or Tumor Necrosis Factor-alpha (TNF-α)
Implementation Method 2
The method and pharmaceutical composition of the present invention can prevent apoptosis in a Retinal Ganglion Cell (RGC), particularly apoptosis induced by hypoxia or Tumor Necrosis Factor-alpha (TNF-α)
Data Source
AI summary
A use method of agmatine or a pharmaceutically allowable salt thereof, and a pharmaceutical composition comprising the same are disclosed. The method and pharmaceutical composition of the present invention can effectively cure or prevent eye diseases preferably including glaucoma, retinopathy, and optic neuropathy associated with apoptosis in retinal ganglion cells (RGCs), particularly hypoxia-induced or tumor necrosis factor-α (TNF-α)-induced apoptosis.